MERISLON

Merislon Adverse Events Reported to the FDA Over Time

How are Merislon adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Merislon, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Merislon is flagged as the suspect drug causing the adverse event.

Most Common Merislon Adverse Events Reported to the FDA

What are the most common Merislon adverse events reported to the FDA?

Alanine Aminotransferase Increased	12 (5.74%)
Aspartate Aminotransferase Increase...	12 (5.74%)
Liver Disorder	9 (4.31%)
Blood Bilirubin Increased	7 (3.35%)
Drug Eruption	7 (3.35%)
Blood Alkaline Phosphatase Increase...	6 (2.87%)
Blood Creatine Phosphokinase Increa...	6 (2.87%)
Blood Creatinine Increased	6 (2.87%)
Blood Pressure Decreased	6 (2.87%)
Blood Urea Increased	6 (2.87%)
C-reactive Protein Increased	6 (2.87%)
	Show More
Dehydration	6 (2.87%)
Erythema	6 (2.87%)
Fibrin Degradation Products Increas...	6 (2.87%)
General Physical Health Deteriorati...	6 (2.87%)
Infection	6 (2.87%)
Multi-organ Failure	6 (2.87%)
Oral Mucosa Erosion	6 (2.87%)
Respiratory Disorder	6 (2.87%)
Skin Erosion	6 (2.87%)
Toxic Epidermal Necrolysis	6 (2.87%)
Gamma-glutamyltransferase Increased	5 (2.39%)
Platelet Count Decreased	4 (1.91%)
Dermatitis Exfoliative	3 (1.44%)
Disseminated Intravascular Coagulat...	3 (1.44%)
Dizziness	3 (1.44%)
Pyrexia	3 (1.44%)
Sepsis	3 (1.44%)
Alpha Tumour Necrosis Factor Increa...	2 (.96%)
Blood Lactate Dehydrogenase Increas...	2 (.96%)
Blood Potassium Decreased	2 (.96%)
Cardiac Arrest	2 (.96%)
Contusion	2 (.96%)
Depressed Level Of Consciousness	2 (.96%)
Drug Interaction	2 (.96%)
Hepatic Function Abnormal	2 (.96%)
Interleukin Level Increased	2 (.96%)
Interstitial Lung Disease	2 (.96%)
Laboratory Test Abnormal	2 (.96%)
Memory Impairment	2 (.96%)
Sudden Hearing Loss	2 (.96%)
Thrombocytopenic Purpura	2 (.96%)
Tinnitus	2 (.96%)
Transient Ischaemic Attack	2 (.96%)
Urinary Incontinence	2 (.96%)
Altered State Of Consciousness	1 (.48%)
Body Temperature Increased	1 (.48%)
Cerebellar Ataxia	1 (.48%)
Endotracheal Intubation	1 (.48%)
Gait Disturbance	1 (.48%)
Jaundice	1 (.48%)
Lymphocyte Stimulation Test Positiv...	1 (.48%)
Malaise	1 (.48%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Merislon, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Merislon is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Merislon

What are the most common Merislon adverse events reported to the FDA?

Hepatobiliary	36 (17.22%)
Epidermal And Dermal Conditions	22 (10.53%)
Enzyme	14 (6.7%)
Hepatic And Hepatobiliary	12 (5.74%)
Renal And Urinary Tract Investigati...	12 (5.74%)
Hematology Investigations	11 (5.26%)
Infections - Pathogen Unspecified	9 (4.31%)
Neurological	7 (3.35%)
Cardiac And Vascular Investigations	6 (2.87%)
Electrolyte And Fluid Balance Condi...	6 (2.87%)
Oral Soft Tissue Conditions	6 (2.87%)
	Show More
Protein And Chemistry Analyses	6 (2.87%)
Respiratory	6 (2.87%)
Skin And Subcutaneous Tissue	6 (2.87%)
Immunology And Allergy	4 (1.91%)
Body Temperature Conditions	3 (1.44%)
Coagulopathies And Bleeding Diathes...	3 (1.44%)
Cardiac Arrhythmias	2 (.96%)
Central Nervous System Vascular	2 (.96%)
Hearing	2 (.96%)
Injuries	2 (.96%)
Inner Ear And Viiith Cranial Nerve	2 (.96%)
Investigations, Imaging And Histopa...	2 (.96%)
Lower Respiratory Tract Disorders	2 (.96%)
Mental Impairment	2 (.96%)
Platelet	2 (.96%)
Therapeutic And Nontherapeutic Effe...	2 (.96%)
Urinary Tract Signs	2 (.96%)
Water, Electrolyte And Mineral	2 (.96%)
Physical Examination Topics	1 (.48%)
Respiratory Tract Therapeutic Proce...	1 (.48%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Merislon, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Merislon is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.